D-Glutamate

D-Glutamate

SCHEMBL1767317

CC(O)C(N)C(=O)O.NC(CCC(=O)O)C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.69
GRM8 O00222 2/20 0.69
GRM6 O15303 2/20 0.69
GRM7 Q14831 2/20 0.69
GRM4 Q14833 2/20 0.69
GRIN2D O15399 1/20 0.69
GRIN3B O60391 1/20 0.69
GSR P00390 1/20 0.69
GRIK1 P39086 1/20 0.69
GRM5 P41594 1/20 0.69
GRIA1 P42261 1/20 0.69
GRIA2 P42262 1/20 0.69
GRIA3 P42263 1/20 0.69
SLC1A3 P43003 1/20 0.69
SLC1A2 P43004 1/20 0.69
SLC1A1 P43005 1/20 0.69
GRIA4 P48058 1/20 0.69
GRIN1 Q05586 1/20 0.69
GRIN2A Q12879 1/20 0.69
GRIK2 Q13002 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL1527702 1.00 CYP1A2 (0.69) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL2501322 1.00 CYP1A2 (0.69) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL25337565 0.95 CYP1A2 (0.62) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27287949 0.93 CYP1A2 (0.60) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27691480 0.93 CYP1A2 (0.60) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL6130151 0.92 SLC1A3 (0.58) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL9716073 0.90 CYP1A2 (0.56) CYP1A2GRM8GRM6GRM7GRM4
Glutamic Acid SCHEMBL9716085 0.90 CYP1A2 (0.56) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL23777456 0.87 SLC1A3 (0.53) CYP1A2GRM8GRM6GRM7GRM4
D-Glutamate SCHEMBL27591999 0.87 CYP1A2 (0.53) CYP1A2GRM8GRM6GRM7GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011053167-A1 TRANSCRIPTION FACTOR POLYNUCLEOTIDES AND THEIR USE GRASSLANZ TECHNOLOGY LIMITED (NZ) 2011-05-05 WO claimed
CN-101134948-A S-adenosine methilanin synthase mutant, DNA encoding the mutant and application of the mutant BIORIGHT WORLDWIDE CO LTD (VG) 2008-03-05 CN claimed
US-20210107977-A1 METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES ALLAKOS INC (US) 2021-04-15 US disclosed
CN-110325546-A DNA MONOCLONAL ANTIBODIES TARGETING INFLUENZA VIRUS 宾夕法尼亚大学理事会 2019-10-11 CN disclosed
CN-110167584-A DNA antibody constructs for targeting lyme disease 威斯塔解剖学和生物学研究所 2019-08-23 CN disclosed
CN-110072554-A DNA antibody construct for resisting pseudomonas aeruginosa 宾夕法尼亚大学理事会 2019-07-30 CN disclosed
CN-109789225-A DNA MONOCLONAL ANTIBODIES TARGETING CHECKPOINT MOLECULES 宾夕法尼亚大学理事会 2019-05-21 CN disclosed
CN-109789224-A DNA MONOCLONAL ANTIBODIES TARGETING IL-6 AND CD126 宾夕法尼亚大学理事会 2019-05-21 CN disclosed
US-8900849-B2 Oxygen-regulated microorganisms SCARAB GENOMICS, LLC (US) 2014-12-02 US disclosed
US-8354372-B2 Cyclised alpha-conotoxin peptides THE UNIVERSITY OF QUEENSLAND (AU) 2013-01-15 US disclosed
WO-2011053167-A1 TRANSCRIPTION FACTOR POLYNUCLEOTIDES AND THEIR USE GRASSLANZ TECHNOLOGY LIMITED (NZ) 2011-05-05 WO disclosed
US-20090053792-A1 OXYGEN-REGULATED MICROORGANISMS SCARAB GENOMICS, LLC (US) 2009-02-26 US disclosed
CN-85101907-A The manufacturing of single segment dominent human r gamma-interferon 1987-01-10 CN disclosed